Share

Save

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

PHASE1RECRUITING

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

info
Simpliy with AI

Study details:

This is a two-part, open-label, multi-center, dose escalation and dose expansion study in participants with BRAF mutation-positive and/or NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787, and to assess the objective response to KIN-2787 therapy alone and in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor. The dose expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class I, II or III mutations, including lung cancer, melanoma, and other selected solid tumors.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Provide written informed consent prior to initiation of any study-specific procedures.
  • Metastatic or advanced stage solid tumor
  • Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA.
  • Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1.
  • ECOG performance status 0-1
  • Adequate organ function, as measured by laboratory values (criteria listed in protocol).
  • Able to swallow, retain, and absorb oral medications.
  • Exclusion criteria

  • Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria)
  • In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy.
  • GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.
  • Active, uncontrolled bacterial, fungal, or viral infection.
  • Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded
  • Women who are lactating or breastfeeding, or pregnant.
  • Participants with any other active treated malignancy within 3 years prior to enrollment
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 18 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2021-08-04

    Primary completion: 2024-12-07

    Study completion finish: 2025-12-01

    study type

    Study type

    TREATMENT

    phase

    Phase

      PHASE1

    trial

    Trial ID

    NCT04913285

    Intervention or treatment

    DRUG: KIN-2787

    DRUG: KIN-2787 and binimetinib

    Conditions

    • Solid Tumor, Adult
    • Non-small Cell Lung Cancer
    • Melanoma
    Image related to Solid Tumor, Adult
    • Condition: Solid Tumor, Adult, Non-small Cell Lung Cancer and more

    • DRUG: KIN-2787 and other drugs

    • Wollstonecraft, New South Wales, Australia and more

    • Sponsor: Pierre Fabre Medicament

    Find a site

    Closest Location:

    Melanoma Institute Australia

    Research sites nearby

    Select from list below to view details:

    • Melanoma Institute Australia

      Wollstonecraft, New South Wales, Australia

    • Linear Clinical Research

      Perth, Western Australia, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: Dose Escalation Monotherapy (Part A1)
    • Dose escalation of KIN-2787
    DRUG: KIN-2787
    • KIN-2787 will be administered orally twice daily in 28-day cycles
    EXPERIMENTAL: Dose Escalation Combination therapy (Part A2)
    • Dose escalation of KIN-2787 and binimetinib
    DRUG: KIN-2787 and binimetinib
    • KIN-2787 and binimetinib will be administered orally twice daily in 28-day cycles
    EXPERIMENTAL: Dose Expansion Monotherapy (Part B1)
    • Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787
    DRUG: KIN-2787
    • KIN-2787 will be administered orally twice daily in 28-day cycles
    EXPERIMENTAL: Dose Escalation Combination therapy (Part B2)
    • Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 and binimetinib
    DRUG: KIN-2787 and binimetinib
    • KIN-2787 and binimetinib will be administered orally twice daily in 28-day cycles

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Part A1 Dose escalation monotherapy:To determine the safety and tolerability of oral administration of KIN-2787 including dose-limiting toxicities (DLTs), and to identify the maximum tolerated dose (MTD) and/or the appropriate dose for further clinical investigation in Part B Dose Expansion.Initiation of study drug through 28 days after last dose (up to approximately 18 months)
    Part A2 Dose Escalation: KIN-2787 + Binimetinib CombinationTo determine the safety and tolerability of oral administration of KIN-2787 + binimetinib including DLTs, and to identify the MTD and/or the appropriate dose for further clinical investigation.Initiation of study drug through 28 days after last dose (up to approximately 18 months)
    In Part B (Dose Expansion) - objective response rate (ORR) using RECIST v1.1.To assess preliminary evidence of the anti-cancer activity of KIN-2787 and for (B2) KIN-2787 + binimetinibInitiation of study drug until disease progression (up to approximately 36 months)
    In Part B (Dose Expansion) - disease control rate (DCR).Not SpecifiedInitiation of study drug until disease progression (up to approximately 36 months)
    In Part B (Dose Expansion) - duration of overall response (DOR).Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progressionInitiation of study drug until disease progression (up to approximately 36 months)
    In Part B (Dose Expansion) - duration of stable disease.Not SpecifiedInitiation of study drug until disease progression (up to approximately 36 months)

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to tmax.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to AUC.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part A1 Dose Escalation: Characterization of PK properties and effect of food on PK of KIN-2787 including, but not limited to Cmax.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to Cmax.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to AUC.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part A2 Dose Escalation: characterization of PK properties of KIN-2787 and binimetinib in combination including, but not limited to tmax.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to AUC.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to Cmax.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)
    Part B Dose Expansion: characterization of PK properties of KIN-2787, and for (B2) KIN-2787 + binimetinib including, but not limited to tmax.Not SpecifiedInitiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

    Other trails to consider

    Top searched conditions